Also known as: Prothena
Prothena is a late-stage clinical biotechnology company focused on protein dysregulation and investigational therapies for rare peripheral amyloid and neurodegenerative diseases. Its portfolio is built on a long scientific legacy that includes work originating from Athena Neurosciences.
Prothena reported Q4 and full year 2025 financial results with $308.4 million in cash as partners Roche and Novo Nordisk initiated Phase 3 trials for prasinezumab and coramitug, both expected to complete in 2029.
Prothena reported Q4 2025 adjusted loss of 45 cents per share, meeting estimates, while ending the year with $308.4 million in cash. Roche and Novo Nordisk advanced partnered programs prasinezumab and coramitug into Phase III trials.
